IP Library Granted Patent US 10,370,432
Granted Patent B2
US 10,370,432 · App. 15/516,582 · Granted Aug 6, 2019

Heterologous targeting peptide grafted AAVS

Inventors: Miguel Sena Esteves (Westford, MA); Sourav Roy Choudhury (Newton, MA)
Assignee: University of Massachusetts
C07K14/775A61K48/0025A61K48/0058C07K7/00C07K7/04C07K14/00C07K14/005C07K14/075C07K19/00C12N15/79C12N15/86C07K2319/01C07K2319/30C07K2319/33C12N2750/14145C12N2810/85
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,370,432
App. No.
15/516,582
Granted
Aug 6, 2019
Kind
B2
Abstract

The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.

Claims (24)

1. An adeno associated virus capsid protein comprising an N-terminally grafted heterologous targeting peptide, wherein:

(i) the capsid protein is a VP2 capsid protein that is not of an AAV2 serotype; and

(ii) the targeting peptide is a CNS-targeting polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 5, that is inserted between the first and second amino acid residues of the VP2 capsid protein.

2. The capsid protein of claim 1 , further comprising a linker conjugated to the C-terminus of the N-terminally grafted heterologous targeting peptide.

3. The capsid protein of claim 2 , wherein the linker comprises at least one polypeptide repeat, each repeat comprising at least two glycine residues.

4. The capsid protein of claim 3 , wherein the linker is of the formula [G] n S, wherein n is an integer in a range of 2 to 10.

5. The capsid protein of claim 3 , wherein the linker comprises the formula [GGGGS] n , wherein n is an integer in a range of 1 to 4.

6. The capsid protein of claim 5 , wherein the linker comprises SEQ ID NO: 28.

7. An adeno associated virus capsid protein comprising an N-terminally grafted heterologous targeting peptide, wherein:

(i) the capsid protein is a VP2 capsid protein that is not of an AAV2 serotype; and

(ii) the targeting peptide is a CNS-targeting polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 7, that is inserted between the first and second amino acid residues of the VP2 capsid protein.

8. The capsid protein of claim 7 , further comprising a linker conjugated to the C-terminus of the N-terminally grafted heterologous targeting peptide.

9. The capsid protein of claim 8 , wherein the linker comprises at least one polypeptide repeat, each repeat comprising at least two glycine residues.

10. The capsid protein of claim 9 , wherein the linker is of the formula [G] n S, wherein n is an integer in a range of 2 to 10.

11. The capsid protein of claim 9 , wherein the linker comprises the formula [GGGGS] n , wherein n is an integer in a range of 1 to 4.

12. The capsid protein of claim 11 , wherein the linker comprises SEQ ID NO:28.

13. An adeno associated virus capsid protein comprising an N-terminally grafted heterologous targeting peptide, wherein:

(i) the capsid protein is a VP2 capsid protein that is not of an AAV2 serotype; and

(ii) the targeting peptide is a CNS-targeting polypeptide encoded by a nucleic acid consisting of the nucleotide sequence set forth in SEQ ID NO: 29, that is inserted between the first and second amino acid residues of the VP2 capsid protein.

14. The capsid protein of claim 13 , further comprising a linker conjugated to the C-terminus of the N-terminally grafted heterologous targeting peptide.

15. The capsid protein of claim 14 , wherein the linker comprises at least one polypeptide repeat, each repeat comprising at least two glycine residues.

16. The capsid protein of claim 15 , wherein the linker is of the formula [G] n S, wherein n is an integer in a range of 2 to 10.

17. The capsid protein of claim 15 , wherein the linker comprises the formula [GGGGS] n , wherein n is an integer in a range of 1 to 4.

18. The capsid protein of claim 17 , wherein the linker comprises SEQ ID NO:28.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2018
From: ESTEVES, MIGUEL SENA; CHOUDHURY, SOURAV ROY
To: UNIVERSITY OF MASSACHUSETTS
Reel/Frame 046484/0537 →
CONFIRMATORY LICENSE Recorded Apr 21, 2017
From: UNIVERSITY OF MASSACHUSETTS MEDICAL SCH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042303/0561 →
Continuity (2)
Provisional Application 62059738 · Oct 3, 2014
Related Publication 20180265571A1 · Sep 20, 2018
Cited By (5)
US 12,291,719 US 12,312,587 US 12,398,181 US 12,529,051 US 12,662,669